A big win for Wegovy: Weight loss drug semaglutide first in history to gain FDA approval for reducing heart risks Semaglutide, a GLP-1 receptor agonist from Novo Nordisk, originally developed to treat diabetes, has been approved by the U.S
Weight loss of at least 5% was observed in 63.2 and 27.1% of the patients, respectively, and weight loss 10% was seen in 33.1 and 10.6% of the patients, respectively
Many users begin to see good results within the first three months, especially when combined with lifestyle changes
Clinically studied for lowering creatinine levels and improving kidney function
Cure Reports Clinician Perspectives on GLP-1 Prescribing for Conditions Beyond Diabetes and Obesity In a new exclusive report, Insights from Specialty Physicians on GLP-1RA Medications Off-Label Use , Cure unveils the results of a specialty physician survey that sheds light on their current prescribing experiences, the challenges they face, and their expectations for future clinical applications of these drugs
